68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Not Applicable

• Conditions: 68Ga-FAPI PET/CT; Metastatic Adenoid Cystic Carcinoma
• Interventions: Drug: 68Ga-FAPI

• Registration Number: NCT05499936
• Lead Sponsor: Peking Union Medical College Hospital

Brief Summary

This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）

Detailed Description

68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma.

Study Timeline

• Status Verified: 2021-10
• Study Start: 2021-10-01
• Study First Submitted: 2022-06-28
• Study First Submitted QC: 2022-08-10
• Last Update Submitted: 2022-08-10
• Study First Posted: 2022-08-12
• Last Update Posted: 2022-08-12
• Primary Completion: 2022-10-01
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• patients with ACC suspected metastatic tumor,and being able to provide basic information and sign the written informed consent form

Exclusion Criteria

• claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
68Ga-FAPI PET/CT	68Ga-FAPI	Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer

Primary Outcome Measures

Name	Time	Method
Standardized uptake value of 68Ga-FAPI in ACC	1 year	The maximum and mean standard uptake values (SUVmax and SUVmean) were measured in the background of lesion, liver, muscle and mediastinal blood pool, respectively.

Secondary Outcome Measures

Name	Time	Method
lesions detected by 68Ga-FAPI PET/CT	1 year	The number of target lesions in each organ system was calculated by 68Ga-FAPI PET/CT

Trial Locations

Locations (1)

Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College; 🇨🇳 Beijing, China